Heart failure (HF) continues to be an illness of daunting proportions with a four- year mortality touching 50%. Biomarkers for prognosticating patients with heart failure have generated immense interest. Several studies have been conducted on a novel biomarker, galectin-3 to assess its prognostic effect in heart failure populations. However, the studies have generated conflicting results. Hence a systematic review was done to assess the utility of galectin-3 as a prognostic biomarker in HF.
Design
This study was a systematic review.
Methods
A literature search was done using terms ‘galectin-3 and heart' and ‘galectin-3 and heart failure' in MEDLINE, Science Direct, Scopus, Springer Link, Cochrane Library and Google Scholar for original articles using a predefined inclusion/exclusion criteria.
Results
Altogether 27 original articles were selected for the systematic review. Multivariate analysis showed galectin-3 to be ineffective in predicting all-cause mortality and cardiovascular mortality especially under the influence of factors such as estimated glomerular filtration rate (eGFR), left ventricular ejection fraction (LVEF) and N-terminal pro-B-type natriuretic peptide (NTproBNP). Galectin-3 was not found to be superior to NTproBNP, sST2, GDF-15 or C-reactive protein (CRP) as a predictor of mortality. However the combination of natriuretic peptides and galectin-3 has been observed to be superior in predicting mortality compared to either of the biomarkers alone. The role of galectin-3 in remodelling has not been conclusively proven as seen in earlier pre-clinical studies.
Conclusion
The current weight of evidence does not suggest galectin-3 to be a predictor of mortality. However, assessment of galectin-3 in a multi-biomarker panel may have a distinct advantage in prognosticating patients with heart failure.
DenolinHKuhnHKrayenbuehlHP. The definition of heart failure. Eur Heart J1983; 4: 445–448.
2.
JessupMBrozenaS. Heart failure. N Engl J Med2003; 348: 2007–2018.
3.
DicksteinKCohen-SolalAFilippatosG. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J2008; 29: 2388–2442.
4.
DoustJAPietrzakEDobsonA. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: Systematic review. Br Med J2005; 330: 625–625.
5.
AhmadTMichael FelkerG. Galectin-3 in heart failure: More answers or more questions?J Am Heart Assoc2012; 1: e004374–e004374.
6.
HugesMFSaarelaOBlankenbergS. A multiple biomarker risk score for guiding clinical decisions using a decision curve approach. Eur J Prev Cardiol2012; 19: 874–884.
7.
BergerRHuelsmanMStreckerK. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation2002; 105: 2392–2397.
8.
WangTJLarsonMGLevyD. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med2004; 350: 655–663.
LefflerHCarlssonSHedlundM. Introduction to galectins. Glycoconj J2004; 19: 433–440.
11.
De BoerRAVoorsAAMuntendamP. Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail2009; 11: 811–817.
12.
De BoerRAYuLvan VeldhuisenDJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep2010; 7: 1–8.
13.
De BoerRALokDJAJaarsmaT. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med2011; 43: 60–68.
14.
HoJELiuCLyassA. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol2012; 60: 1249–1256.
15.
FelkerGMFiuzatMShawLK. Galectin-3 in ambulatory patients with heart failure: Results from the HF-ACTION study. Circ Heart Fail2012; 5: 72–78.
16.
HemingwayHPhilipsonPChenR. Evaluating the quality of research into a single prognostic biomarker: A systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med2010; 7: e1000286–e1000286.
17.
MayrAKlugGMairJ. Galectin-3: Relation to infarct scar and left ventricular function after myocardial infarction. Int J Cardiol2013; 163: 335–337.
18.
GrandinEWJarolimPMurphySA. Galectin-3 and the development of heart failure after acute coronary syndrome: Pilot experience from PROVE IT-TIMI 22. ClinChem2012; 58: 267–273.
19.
WeirRAPPetrieCJMurphyCA. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail2013; 6: 492–498.
20.
MotiwalaSRSzymonifkaJBelcherA. Serial measurement of galectin-3 in patients with chronic heart failure: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail2013; 15: 1157–1163.
21.
De BoerRAvan VeldhuisenDJGansevoortRT. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med2012; 272: 55–64.
22.
DanielsLBCloptonPLaughlinGA. Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study. Am Heart J2014; 167: 674–682.
23.
GullestadLUelandTKjekshusJ. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J2012; 164: 878–883.
24.
Bayes-GenisAde AntonioMVilaJ. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol2014; 63: 158–166.
25.
SharmaUCPokharelSvan BrakelTJ. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation2004; 110: 3121–3128.
26.
ChenKJiangR-JWangC-Q. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci2013; 17: 1005–1011.
27.
GopalDMKommineniMAyalonN. Relationship of plasma galectin-3 to renal function in patients with heart failure: Effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J Am Heart Assoc2012; 1: e000760–e000760.
28.
LokDJAVan Der MeerPde la PortePWB-A. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol2010; 99: 323–328.
29.
Lopez-AndrèsNRossignolPIraqiW. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: Insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail2012; 14: 74–81.
30.
HendersonNCMackinnonACFarnworthSL. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol2008; 172: 288–298.
31.
Beiras-FernandezAWeisFRothkopfJ. Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation. Ann Transplant Q Pol Transplant Soc2013; 18: 643–650.
32.
TangWHWShresthaKShaoZ. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol2011; 108: 385–390.
33.
GaitaDMihaescuASchillerA. Of heart and kidney: A complicated love story. Eur J Prev Cardiol2012; 21: 840–846.
34.
TunonJBlanco-ColioLCristobalC. Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and n-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease. Am J Cardiol2014; 113: 434–440.
LiuF-TRabinovichGA. Galectins: Regulators of acute and chronic inflammation. Ann N Y Acad Sci2010; 1183: 158–182.
37.
YancyCWJessupMBozkurtB. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol2013; 62: 1495–1539.
38.
KramerFMiltingH. Novel biomarkers in human terminal heart failure and under mechanical circulatory support. Biomarkers2011; 16: S31–S41.
39.
KnightBXueYMaiselAS. Galectin-3: Newest marker of HF outcomes. Curr Emerg Hosp Med Rep.2014; 2: 112–119.
40.
HlatkyMAGreenlandPArnettDK. Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American Heart Association. Circulation2009; 119: 2408–2416.
41.
LokDJKlipITLokSI. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol2013; 112: 831–837.
42.
Van KimmenadeRRJanuzziJLJrEllinorPT. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol2006; 48: 1217–1224.
43.
AnandISRectorTSKuskowskiM. Baseline and serial measurements of galectin-3 in patients with heart failure: Relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail2013; 15: 511–518.
44.
ToprakGYükselHDemirpençeÖ. Fibrosis in heart failure subtypes. Eur Rev Med Pharmacol Sci2013; 17: 2302–2309.
45.
Vergaro G, Franco AD, Prontera C, et al. Galectin-3 and myocardial fibrosis at cardiac magnetic resonance in nonischemic dilated cardiomyopathy. J Am Coll Cardiol. Epub ahead of print 1 April 2014. DOI:10.1016/s0735-1097(14)60800-7.
46.
Carrasco-SánchezFJAramburu-BodasOSalamanca-BautistaP. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol2013; 169: 177–182.
47.
FermannGJLindsellCJStorrowAB. Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers2012; 17: 706–713.
48.
LokDJLokSIBruggink-André de la PortePW. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol2013; 102: 103–110.
49.
ShahRVChen-TournouxAAPicardMH. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail2010; 12: 826–832.
50.
UelandTAukrustPBrochK. Galectin-3 in heart failure: High levels are associated with all-cause mortality. Int J Cardiol2011; 150: 361–364.
51.
YinQSShiBDongL. Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure. J Geriatr Cardiol2014; 11: 7982–82.
